Skip to main content
. Author manuscript; available in PMC: 2014 Nov 24.
Published in final edited form as: Circ Heart Fail. 2013 Jul 23;6(5):988–997. doi: 10.1161/CIRCHEARTFAILURE.113.000372

Table 1.

Hazard Ratios for the Primary End Point for Individual Cox Models*

Warfarin
 Aspirin
 Hazard Ratio (95% CI) for
Warfarin vs Aspirin		 P Value
Events/Patients Rate† Events/Patients Rate† For HR‡ For Interaction§
Age group, y
  <60 93/508 4.81 130/522 6.76 0.65 (0.49–0.86) 0.002 0.001
  ≥60 209/634 9.91 190/641 9.01 1.16 (0.94–1.43) 0.16
Country
  Poland 34/129 7.70 50/134 12.38 0.61 (0.40–0.95) 0.03
  Ukraine 20/57 9.68 28/58 13.75 0.78 (0.43–1.43) 0.43
  United States 115/463 6.06 130/440 7.55 0.79 (0.61–1.02) 0.07 0.02
  Argentina and other European 68/308 7.75 67/348 6.57 1.18 (0.84–1.67) 0.34
  Hungary 30/75 13.06 22/77 9.34 1.29 (0.73–2.28) 0.38
  Canada 35/110 8.90 23/106 5.12 1.69 (0.98–2.90) 0.06
Sex
  Men 240/906 7.55 281/939 8.71 0.88 (0.73–1.05) 0.16 0.07
  Women 62/236 7.17 39/224 4.83 1.34 (0.88–2.03) 0.17
Smoking
  Current 46/213 5.96 63/195 9.30 0.62 (0.41–0.92) 0.02
  Former 173/585 8.29 178/604 8.50 0.98 (0.78–1.22) 0.84 0.08
  Never 83/344 6.99 79/364 6.26 1.10 (0.80–1.53) 0.55
NYHA class
  NYHA 3 or 4 116/368 9.12 131/347 11.72 0.78 (0.60–1.01) 0.06 0.11
  NYHA 1 or 2 186/774 6.71 189/816 6.48 1.03 (0.83–1.26) 0.82
Prior stroke or TIA 45/155 8.39 56/139 12.56 0.72 (0.47–1.11) 0.14 0.21
No prior stroke or TIA 257/987 7.33 264/1024 7.36 0.98 (0.82–1.17) 0.79
Statin
  No 21/137 6.80 29/147 9.42 0.77 (0.42–1.39) 0.39
  Unknown 92/315 6.79 112/312 8.58 0.78 (0.59–1.04) 0.09 0.22
  Yes 189/690 7.94 179/704 7.40 1.06 (0.85–1.31) 0.61
Hemoglobin
  Low 180/613 8.31 184/586 9.25 0.84 (0.67–1.04) 0.11 0.23
  High 122/529 6.50 136/577 6.65 1.03 (0.80–1.33) 0.81
6-minute walk, m
  High 97/499 5.49 126/550 6.60 0.81 (0.61–1.06) 0.12 0.24
  Low 205/643 9.00 194/613 9.14 0.99 (0.81–1.22) 0.94
Diabetes mellitus
  No 177/771 6.37 201/812 7.06 0.86 (0.70–1.06) 0.16 0.25
  Yes 125/371 9.86 119/351 10.05 1.06 (0.81–1.39) 0.67
Aspirin or other antiplatelet, prior use
  Unknown 88/304 6.77 99/288 8.34 0.75 (0.55–1.02) 0.06
  No 38/221 7.67 36/233 6.97 1.01 (0.63–1.62) 0.96 0.25
  Yes 176/617 7.83 185/642 7.94 1.03 (0.83–1.27) 0.82
BUN
  Low 126/555 6.03 151/598 6.95 0.83 (0.65–1.07) 0.15 0.26
  High 176/587 9.00 169/565 9.08 1.01 (0.81–1.26) 0.93
BMI category
  >30 89/415 5.75 106/428 6.95 0.82 (0.61–1.10) 0.18
  <25 91/294 9.08 92/265 10.52 0.84 (0.61–1.14) 0.26 0.27
  25–30 122/433 8.17 122/470 7.47 1.10 (0.84–1.44) 0.47
Warfarin, prior use
  Yes 26/90 7.72 27/89 8.62 0.69 (0.38–1.23) 0.21 0.29
  No 276/1052 7.44 293/1074 7.88 0.96 (0.81–1.13) 0.60
Device
  No 236/870 7.61 268/911 8.35 0.89 (0.75–1.07) 0.23 0.32
  Yes 66/272 7.00 52/252 6.33 1.11 (0.76, 1.63) 0.59
eGFR
  High 115/549 5.71 141/591 6.62 0.83 (0.65–1.08) 0.17 0.36
  Low 187/593 9.22 179/572 9.41 0.98 (0.79–1.22) 0.84
WBC
  High 144/590 6.76 166/596 8.28 0.87 (0.69–1.10) 0.23 0.40
  Low 158/552 8.25 154/567 7.59 1.00 (0.79–1.27) 0.98
Myocardial infarction
  No 144/593 6.73 155/600 7.30 0.87 (0.69–1.11) 0.26 0.43
  Yes 158/549 8.30 165/563 8.64 1.00 (0.79–1.26) 0.998
Education
  College grad 32/163 4.96 52/193 6.99 0.72 (0.45–1.14) 0.16
  High School grad 134/487 7.36 130/460 8.04 0.92 (0.71–1.19) 0.52 0.45
  Less than High School 136/492 8.62 138/510 8.25 1.01 (0.79–1.29) 0.96
Alcohol use
  Current 63/279 6.23 67/293 6.73 0.80 (0.56–1.15) 0.23
  Former 73/250 7.85 87/256 9.31 0.87 (0.62–1.22) 0.42 0.49
  Never 166/613 7.89 166/614 7.89 1.02 (0.82–1.28) 0.85
Sodium
  High 160/611 7.30 167/608 7.82 0.89 (0.71–1.12) 0.32 0.55
  Low 142/531 7.66 153/555 8.06 0.99 (0.78–1.25) 0.92
Mini-mental status examination
  Low 121/397 8.91 127/415 8.93 0.88 (0.67–1.14) 0.33 0.58
  High 181/745 6.74 193/748 7.40 0.97 (0.78–1.19) 0.75
Coronary artery disease
  No 109/491 5.96 112/480 6.39 0.88 (0.67–1.18) 0.41 0.62
  Yes 193/651 8.71 208/683 9.13 0.97 (0.79–1.20) 0.80
Atrial fibrillation
  Yes 14/44 8.91 13/42 9.93 0.78 (0.33–1.80) 0.55 0.67
  No 288/1098 7.41 307/1121 7.87 0.94 (0.79–1.11) 0.45
Diastolic blood pressure
  High 133/577 6.38 142/587 6.92 0.89 (0.70–1.14) 0.38 0.67
  Low 169/565 8.62 178/576 8.98 0.96 (0.77–1.20) 0.74
PVD
  No 158/560 7.87 171/575 8.54 0.92 (0.76–1.09) 0.33 0.68
  Yes 144/582 7.07 149/588 7.34 1.01 (0.67–1.52) 0.97
Ischemic cardiomyopathy
  No 147/654 6.01 155/660 6.39 0.91 (0.72–1.15) 0.43 0.70
  Yes 155/488 9.68 165/503 10.28 0.97 (0.77–1.23) 0.82
Race/ethnicity
  Hispanic 17/85 6.62 18/81 8.42 0.67 (0.33–1.33) 0.25
  Black 48/166 7.37 47/166 7.63 0.92 (0.59–1.41) 0.69 0.79
  White 229/859 7.56 245/879 7.98 0.96 (0.80–1.16) 0.67
  Other 8/32 7.51 10/37 7.44 0.98 (0.37–2.61) 0.97
Hypertension
  Unknown 12/38 7.75 13/35 9.52 0.82 (0.34–1.95) 0.65
  Yes 167/671 7.15 190/696 8.06 0.90 (0.72–1.12) 0.33 0.83
  No 123/433 7.91 117/432 7.60 0.99 (0.76–1.29) 0.93
Hematocrit
  High 128/552 6.6 143/577 7.07 0.87 (0.52–1.47) 0.61 0.83
  Low 174/590 8.27 177/586 8.80 0.91 (0.73–1.13) 0.38
Systolic blood pressure
  Low 158/560 7.87 171/575 8.54 0.92 (0.73–1.16) 0.48 0.88
  High 144/582 7.07 149/588 7.34 0.94 (0.74–1.20) 0.64
Ejection fraction
  Middle 83/283 8.04 76/269 8.00 0.90 (0.71–1.15) 0.41
  High 59/261 6.09 81/272 8.26 0.93 (0.65–1.33) 0.70 0.97
  Low 100/305 9.48 89/298 8.80 0.95 (0.70–1.28) 0.72

BMI indicates body mass index; BUN, blood urea nitrogen; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; NYHA, New York Heart Association; PVD, peripheral vascular disease; TIA, transient ischemic attack; and WBC, white blood cell.

*

Each model includes terms for treatment, baseline variable, and treatment×baseline variable interaction. Variables are presented in increasing order of P value for the interaction term. Within variables, subgroups are in increasing order of the HR.

†

Rates are per 100 patient-years.

‡

P value for the HR.

§

P value for the test for treatment×baseline variable interaction in a Cox model stratified by site, prior stroke status, and NYHA classification.